Cognition Therapeutics (CGTX) News Today

Cognition Therapeutics, Inc. (NASDAQ:CGTX - Get Free Report) saw a significant increase in short interest in the month of June. As of June 30th, there was short interest totalling 208,100 shares, an increase of 15.2% from the June 15th total of 180,700 shares. Approximately 0.6% of the shares of the company are sold short. Based on an average daily trading volume, of 147,000 shares, the short-interest ratio is presently 1.4 days.

Cognition Therapeutics, Inc. (NASDAQ:CGTX - Get Free Report) has been assigned a consensus recommendation of "Buy" from the six analysts that are covering the firm, MarketBeat reports. Six investment analysts have rated the stock with a buy recommendation. The average 12-month price target among b

Cognition Therapeutics, Inc. (NASDAQ:CGTX - Get Free Report) was the target of a significant decline in short interest during the month of June. As of June 15th, there was short interest totalling 180,700 shares, a decline of 14.2% from the May 31st total of 210,600 shares. Currently, 0.5% of the company's stock are sold short. Based on an average trading volume of 144,300 shares, the short-interest ratio is currently 1.3 days.

Cognition Therapeutics, Inc. (NASDAQ:CGTX - Free Report) - Equities research analysts at B. Riley increased their Q2 2024 earnings per share estimates for shares of Cognition Therapeutics in a research note issued on Wednesday, June 12th. B. Riley analyst M. Mamtani now forecasts that the company

Cognition Therapeutics, Inc. (NASDAQ:CGTX - Get Free Report) was the recipient of a significant increase in short interest in the month of May. As of May 31st, there was short interest totalling 210,600 shares, an increase of 71.9% from the May 15th total of 122,500 shares. Currently, 0.6% of the company's shares are sold short. Based on an average daily trading volume, of 166,400 shares, the days-to-cover ratio is currently 1.3 days.

Chardan Capital initiated coverage on shares of Cognition Therapeutics in a report on Thursday. They issued a "buy" rating and a $11.00 target price for the company.

Cognition Therapeutics, Inc. (NASDAQ:CGTX - Free Report) - Stock analysts at Cantor Fitzgerald lowered their FY2024 earnings per share estimates for Cognition Therapeutics in a research note issued to investors on Wednesday, May 29th. Cantor Fitzgerald analyst C. Duncan now expects that the compa

Cognition Therapeutics, Inc. (NASDAQ:CGTX - Free Report) - Equities researchers at HC Wainwright issued their Q2 2024 earnings per share estimates for shares of Cognition Therapeutics in a research note issued on Wednesday, May 29th. HC Wainwright analyst R. Selvaraju forecasts that the company w

HC Wainwright began coverage on shares of Cognition Therapeutics in a research note on Wednesday. They issued a "buy" rating and a $10.00 price objective on the stock.

Cognition Therapeutics, Inc. (NASDAQ:CGTX - Get Free Report) saw a significant decline in short interest during the month of March. As of March 31st, there was short interest totalling 150,200 shares, a decline of 34.2% from the March 15th total of 228,100 shares. Based on an average trading volume of 204,700 shares, the days-to-cover ratio is currently 0.7 days. Approximately 0.5% of the company's shares are sold short.

B. Riley reissued a "buy" rating and set a $5.00 price target on shares of Cognition Therapeutics in a research report on Thursday.

Oppenheimer reaffirmed an "outperform" rating and issued a $9.00 price target on shares of Cognition Therapeutics in a research note on Wednesday.

Cognition Therapeutics, Inc. (NASDAQ:CGTX - Get Free Report) saw a significant increase in short interest in the month of February. As of February 29th, there was short interest totalling 126,800 shares, an increase of 26.2% from the February 14th total of 100,500 shares. Based on an average trading volume of 234,900 shares, the days-to-cover ratio is currently 0.5 days. Approximately 0.6% of the company's shares are sold short.